Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index.

ABSTRACT:

Background

Reduction in glucocorticoid exposure is the primary benefit of new biologic treatments in severe asthma, but there is currently no evidence that reduction in glucocorticoid exposure corresponds to a proportionate reduction in associated toxicity.

Objectives

To use the validated Glucocorticoid Toxicity Index (GTI) to assess change in glucocorticoid toxicity after 12 months treatment with mepolizumab, and compare toxicity change to glucocorticoid reduction and change in patient-reported outcome measures (PROMs).

Methods

A longitudinal, real-world prospective cohort of 101 consecutive patients with severe asthma commenced on mepolizumab in a specialist UK regional severe asthma clinic. GTI toxicity assessment, cumulative glucocorticoid exposure and PROMs were

SUBMITTER: McDowell PJ 

PROVIDER: S-EPMC8770919 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature